Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 2/20 | 0.42 |
| ▸ | PEPD | P12955 | 2/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9907299 | 0.84 | HDAC1 (0.34) | ANPEPMMP2 | |
| SCHEMBL9907285 | 0.84 | MMP2 (0.31) | ANPEPMMP2 | |
| SCHEMBL9907290 | 0.77 | ITGB3 (0.34) | MMP2 | |
| SCHEMBL8221483 | 0.76 | PRCP (0.42) | PEPDPRCPXPNPEP1 | |
| SCHEMBL9907298 | 0.75 | TGM2 (0.43) | — | |
| SCHEMBL1942510 | 0.75 | HDAC1 (0.41) | ANPEPMMP2PEPD | |
| SCHEMBL8320214 | 0.75 | HDAC1 (0.41) | ANPEPMMP2PEPD | |
| SCHEMBL2610958 | 0.75 | HDAC1 (0.41) | ANPEPMMP2PEPD | |
| SCHEMBL4430070 | 0.75 | HDAC1 (0.41) | ANPEPMMP2PEPD | |
| SCHEMBL8026939 | 0.75 | HDAC1 (0.41) | ANPEPMMP2PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | ANPEP 86/4885MMP2 82/4885PEPD 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.